The estimated Net Worth of Gordon J. Fehr is at least $3.56 Milión dollars as of 13 April 2015. Gordon Fehr owns over 20,000 units of Merrimack Pharmaceuticals Inc stock worth over $3,557,714 and over the last 13 years Gordon sold MACK stock worth over $0.
Gordon has made over 6 trades of the Merrimack Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Gordon exercised 20,000 units of MACK stock worth $34,200 on 13 April 2015.
The largest trade Gordon's ever made was exercising 25,000 units of Merrimack Pharmaceuticals Inc stock on 12 May 2014 worth over $31,250. On average, Gordon trades about 8,689 units every 111 days since 2012. As of 13 April 2015 Gordon still owns at least 235,143 units of Merrimack Pharmaceuticals Inc stock.
You can see the complete history of Gordon Fehr stock trades at the bottom of the page.
Gordon's mailing address filed with the SEC is C/O MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE, MA, 02139.
Over the last 13 years, insiders at Merrimack Pharmaceuticals Inc have traded over $1,152,598 worth of Merrimack Pharmaceuticals Inc stock and bought 3,978,994 units worth $28,464,218 . The most active insiders traders include Eric Western Standard Llcwe..., Robert J. Mulroy a Gary L Crocker. On average, Merrimack Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $459,997. The most recent stock trade was executed by Eric Western Standard Llcwe... on 26 December 2023, trading 49,550 units of MACK stock currently worth $651,583.
merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. through systems biology, which brings together the fields of biology, computing and engineering, merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. such an approach has the potential to make individualized treatment of patients a reality. merrimack's first commercial product, onivydetm (irinotecan liposome injection), was approved by the u.s. fda on october 22, 2015. with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, merrimack is building one of the most robust oncology pipelines in the industry. for more information, please visit merrimack's website at www.merrimack.com or connect on twitter at @merrimackpharma.
Merrimack Pharmaceuticals Inc executives and other stock owners filed with the SEC include: